Definium tees up regulatory submission for psychedelic on Phase III hat trick
Definium Therapeutics plans to submit an NDA for LSD-based psychedelic, DT120 in generalised anxiety disorder (GAD) during H1 2027.
The post Definium tees up regulatory submission for psychedelic on Phase III hat trick appeared first on Clinical Trials Arena .